BioNexus Gene Lab Corp. has announced the regional deployment of its VitaGuard™ Minimal Residual Disease (MRD) platform across Southeast Asia, marking a significant expansion of its precision diagnostics infrastructure. The company is transitioning VitaGuard™ from a technological innovation to a scalable oncology solution, aiming to replace costly legacy cancer monitoring systems in the region. As part of this initiative, BioNexus has established Fidelion Diagnostics Pte. Ltd. to manage intellectual property and commercialization outside China and is actively recruiting technical, operational, and commercial staff. The expansion also includes preparations for market entry with a regional diagnostics partner and the launch of upgraded global patent filings to support the platform’s growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9644277-en) on January 28, 2026, and is solely responsible for the information contained therein.